Zydus Lifesciences’ Sentynl Licenses Progeria Drug from PRG S&T
Filing Summary
Zydus Lifesciences Ltd’s subsidiary, Sentynl Therapeutics, has entered into an agreement with PRG S&T to license the investigational drug Progerinin for Hutchinson-Gilford Progeria Syndrome (HGPS). The agreement grants Sentynl full rights to the molecule upon meeting certain milestones. Progerinin, designated as an orphan drug by the FDA, is in Phase 2A clinical trials with data expected by mid-2026. This acquisition adds to Sentynl’s portfolio of rare disease therapies. The collaboration aims to advance the clinical development of Progerinin, which targets the genetic disorder causing accelerated aging in children.
Sentynl Therapeutics, a wholly-owned subsidiary of Zydus Lifesciences Limited, has announced an agreement with PRG S&T to license the investigational molecule Progerinin (SLC-D011) for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS). This agreement allows Sentynl to acquire full rights to the molecule, contingent upon the achievement of specific milestones. Progerinin is currently in the final stages of a Phase 2A clinical trial, with data anticipated by the end of the first half of 2026. The drug has been designated as an orphan drug by the United States Food and Drug Administration (FDA).
The financial terms of the agreement between Sentynl and PRG S&T have not been disclosed in the filing. However, the acquisition of Progerinin is a strategic addition to Sentynl’s commercial portfolio, which focuses on rare and ultra-rare disease products. The agreement outlines that Sentynl will gain full rights to Progerinin for HGPS, enhancing its therapeutic offerings in the rare disease sector.
Operationally, the agreement enables Sentynl to collaborate with PRG S&T to advance the clinical development of Progerinin. The drug is an orally active small-molecule designed to inhibit the interaction and harmful effects of progerin within cells, thereby improving nuclear integrity and reducing cellular damage. Progerinin targets the genetic disorder characterized by accelerated aging in children, caused by mutations in the LMNA gene.
The timeline for the development of Progerinin includes the completion of the ongoing Phase 2A clinical trial. Data from this trial are expected before the end of the first half of 2026. The agreement allows Sentynl to begin immediate collaboration with PRG S&T to further the clinical development process, with the aim of advancing Progerinin through subsequent trial phases.
The parties involved in this agreement include Sentynl Therapeutics, a U.S.-based biopharmaceutical company, and PRG S&T, a Korean company specializing in the development of medicine for rare genetic diseases. Sentynl is responsible for the clinical development and potential commercialization of Progerinin, while PRG S&T provides the investigational molecule and expertise in rare genetic disorders.
In the context of the rare disease market, Progerinin represents a potential new therapeutic option for HGPS, a rare genetic disorder with limited treatment options. Currently, Zokinvy® (lonafarnib) is the only approved treatment for HGPS in several regions, including the U.S., European Union, and Japan. The development of Progerinin could provide an alternative treatment for patients with this ultra-rare condition.
PRG S&T is a research and development company focused on treatments for rare genetic diseases. The company specializes in developing therapeutics for conditions such as laminopathies and neurodegenerative diseases using small molecules derived from target sites on aberrant protein-protein interactions.
Zydus Lifesciences Limited is an innovation-led life-sciences company with a strong presence in pharmaceuticals and consumer wellness. The company is committed to advancing healthcare solutions through quality research and development, with a global footprint across the United States, India, and other international markets.